Moleculin Biotech Inc (MBRX) - Total Assets
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) holds total assets worth $20.35 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Moleculin Biotech Inc net assets for net asset value and shareholders' equity analysis.
Moleculin Biotech Inc - Total Assets Trend (2015–2024)
This chart illustrates how Moleculin Biotech Inc's total assets have evolved over time, based on quarterly financial data.
Moleculin Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Moleculin Biotech Inc's total assets of $20.35 Million consist of 30.7% current assets and 69.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.3% |
| Accounts Receivable | $20.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.15 Million | 65.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Moleculin Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Moleculin Biotech Inc (MBRX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Moleculin Biotech Inc's current assets represent 30.7% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 25.3% of total assets in 2024, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 65.9% of total assets.
Moleculin Biotech Inc Competitors by Total Assets
Key competitors of Moleculin Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Moleculin Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 2.08 | 5.89 |
| Quick Ratio | 1.39 | 2.08 | 5.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.20 Million | $6.01 Million | $14.28 Million |
Moleculin Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Moleculin Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 476.20 |
| Latest Market Cap to Assets Ratio | 1.33 |
| Asset Growth Rate (YoY) | -55.7% |
| Total Assets | $16.93 Million |
| Market Capitalization | $22.47 Million USD |
Valuation Analysis
Above Book Valuation: The market values Moleculin Biotech Inc's assets above their book value (1.33x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Moleculin Biotech Inc's assets decreased by 55.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Moleculin Biotech Inc (2015–2024)
The table below shows the annual total assets of Moleculin Biotech Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $16.93 Million | -55.71% |
| 2023-12-31 | $38.22 Million | -33.45% |
| 2022-12-31 | $57.42 Million | -31.71% |
| 2021-12-31 | $84.09 Million | +188.37% |
| 2020-12-31 | $29.16 Million | +15.55% |
| 2019-12-31 | $25.23 Million | +28.85% |
| 2018-12-31 | $19.59 Million | +0.52% |
| 2017-12-31 | $19.48 Million | +18.85% |
| 2016-12-31 | $16.39 Million | +58256.54% |
| 2015-12-31 | $28.09K | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more